2025年1至6月份，天宇股份的营业收入构成为：仿制药原料药及中间体占比72.18%，CDMO原料药及 中间体占比16.02%，制剂占比11.43%，其他占比0.37%。 截至发稿，天宇股份市值为92亿元。 每经AI快讯，天宇股份（SZ 300702，收盘价：26.5元）11月18日晚间发布公告称，公司第五届第十七 次董事会会议于2025年11月18日在公司一楼会议室以现场结合通讯表决的方式召开。会议审议了《关于 确认董事会审计委员会成员及召集人的议案》等文件。 每经头条（nbdtoutiao）——段睿：我与蔡磊是 "找钥匙的人"，纵使生前寻不到，也要为其他渐冻症患 者铺就近路 （记者 曾健辉） ...

Core Viewpoint - Tianyu Co., Ltd. has experienced a stock price increase of 51.72% year-to-date, but has seen a slight decline in recent trading days, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Tianyu Co., Ltd. achieved a revenue of 2.287 billion yuan, representing a year-on-year growth of 18.36% [2]. - The net profit attributable to shareholders for the same period was 221 million yuan, showing a significant year-on-year increase of 159.57% [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Tianyu Co., Ltd. was 15,200, a decrease of 8.06% from the previous period [2]. - The average number of circulating shares per shareholder increased by 8.76% to 13,857 shares [2]. Dividend Distribution - Since its A-share listing, Tianyu Co., Ltd. has distributed a total of 303 million yuan in dividends, with 34.8 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth largest circulating shareholder, holding 6.144 million shares, an increase of 2.7532 million shares from the previous period [3].

Core Viewpoint - Tianyu Co., Ltd. is a leading domestic pharmaceutical raw material enterprise, focusing on the research and production of pharmaceutical intermediates, raw materials, and formulations, with significant technical and cost advantages [1] Financial Performance - In Q3 2025, Tianyu's revenue reached 2.287 billion yuan, ranking 8th in the industry out of 47 companies, with the industry leader, Prolo Pharmaceutical, generating 7.764 billion yuan [2] - The net profit for the same period was 221 million yuan, placing Tianyu 11th in the industry, while the top performer, Zhejiang Pharmaceutical, reported 867 million yuan [2] Profitability and Debt Ratios - As of Q3 2025, Tianyu's debt-to-asset ratio was 43.32%, down from 45.02% year-on-year, which is higher than the industry average of 27.75% [3] - The gross profit margin for the same period was 39.14%, an increase from 35.47% year-on-year, surpassing the industry average of 35.38% [3] Executive Compensation - The chairman and general manager, Tu Yongjun, received a salary of 1.688 million yuan in 2024, an increase of 670,000 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.06% to 15,200, while the average number of shares held per shareholder increased by 8.76% to 13,900 [5] - Hong Kong Central Clearing Limited is the fifth-largest shareholder, holding 6.144 million shares, an increase of 2.7532 million shares from the previous period [5] Business Highlights - The company has seen high growth in non-sartan products, CDMO, and formulations, with continuous improvement in profitability [5] - In H1 2025, revenue from the generic drug raw materials and intermediates business, particularly for blood sugar-lowering and anti-asthma products, grew rapidly [6] - The CDMO business benefited from expanded customer demand, while the formulation business saw improvements due to product structure optimization and marketing channel development [6]

Group 1 - Tianyu Co., Ltd. (SZ 300702) held its 15th meeting of the 5th board of directors on September 29, 2025, to discuss the proposal for the extension of certain fundraising investment projects [1] - For the first half of 2025, Tianyu's revenue composition was as follows: 72.18% from generic drug raw materials and intermediates, 16.02% from CDMO raw materials and intermediates, 11.43% from formulations, and 0.37% from others [1] - As of the report date, Tianyu's market capitalization was 8.9 billion yuan [1] Group 2 - The competition between Farmer and Yibao has intensified, with Farmer's green bottle launch leading to a nearly 5 percentage point drop in Yibao's market share [1]

Group 1 - Tianyu Co., Ltd. stock price on August 25 was 27.57 yuan, a decrease of 0.03 yuan or 0.11% from the previous trading day [1] - The opening price on the same day was 27.45 yuan, with a highest point of 27.80 yuan and a lowest point of 27.20 yuan, achieving a trading volume of 243 million yuan and a turnover rate of 4.18% [1] - The company operates in the chemical pharmaceutical sector, focusing on generic drug raw materials and intermediates, CDMO raw materials and intermediates, and formulations [1] Group 2 - In the first half of 2025, the company achieved operating revenue of 1.567 billion yuan, representing a year-on-year growth of 23.87%, with a gross profit margin increase to 38% [1] - On August 24, the company hosted a research meeting with several institutions including Huachuang Securities, CICC, and CITIC Securities, where executives discussed the operating conditions of the first half of the year and addressed investor concerns [1] - On August 25, the net outflow of main funds from the company was 2.5081 million yuan, accounting for 0.04% of the circulating market value, while the net inflow over the past five days was 48.9456 million yuan, representing 0.84% of the circulating market value [1]

Group 1 - Tianyu Co., Ltd. announced a total asset impairment provision of 72.1642 million yuan for the first half of 2025, in compliance with accounting standards and relevant policies [1] - The company's revenue composition for the first half of 2025 includes 72.18% from generic drug raw materials and intermediates, 16.02% from CDMO raw materials and intermediates, 11.43% from formulations, and 0.37% from other sources [1] - As of the announcement, Tianyu Co., Ltd. has a market capitalization of 9.6 billion yuan [1]